Clinical trials: Involutional
Involutional Osteoporosis
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
- Trial name
- NCT00212667
- Testing
- ONO-5920
- Volunteers
- 650 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Involutional Osteoporosis
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
- Trial name
- NCT00212628
- Testing
- Minodronic acid hydrate
- Where
- 9 sites in Japan
- Volunteers
- 444 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Osteoporosis, Bone Loss, Age-Related
ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.
- Trial name
- NCT00794443
- Testing
- YM529 / ONO-5920
- Where
- 5 sites in Japan
- Volunteers
- 692 people
- Sponsor
- Astellas Pharma Inc
Involutional Osteoporosis
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.
- Trial name
- NCT00212719
- Testing
- ONO-5920
- Volunteers
- 250 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00072774
- Testing
- DVS-233 SR
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteoporosis Postmenopausal
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo…
- Trial name
- NCT00620113
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 287 people
- Sponsor
- Merck Sharp & Dohme LLC
Involutional Osteoporosis
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
The present phase II/III, multicenter, randomized, double-blind, parallel group comparative study is designed to evaluate the efficacy and safety of once-monthly oral administration of NE-58095 delayed release (DR) tablets for 12…
- Trial name
- NCT02063854
- Testing
- NE-58095 IR, NE-58095 DR
- Where
- 25 sites in Japan
- Volunteers
- 871 people
- Sponsor
- Takeda
Major Depressive Disorder
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation…
- Trial name
- NCT00063206
- Testing
- DVS-233 SR
- Volunteers
- 247 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer